Hunan Zhaotai Enterprise Management

Hunan Zhaotai Medical Group is a clinical-stage biotechnology company based in Changsha, China, specializing in the development of next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on addressing both hematological malignancies and challenging solid tumors, such as liver cancer, through its proprietary cell engineering platforms. Zhaotai has advanced several candidates into clinical trials, including therapies targeting CD19, CD22, and GPC3, and has gained recognition for its research in dual-targeting and sequential CAR-T applications. The group operates a comprehensive ecosystem encompassing R&D, clinical translation, and specialized medical services within the regenerative medicine sector.